Antibodies against deamidated gliadin peptides in the diagnosis of celiac disease

Abstract

Celiac disease (CD), a.k.a. gluten enteropathy is a global health problem due to its prevalence of up to 1% in the general population and the high risk of multiorgan complications. Along with confirmed anti-gliadin antibodies, anti-tissue transglutaminase antibodies, anti-endomysium antibodies, etc., in the diagnosis of CD, results on antibodies to deamidated gliadin peptides (anti-DGP antibodies) have been accumulated in the past ten years. Anti-DGP antibodies have shown comparable and even better characteristics in terms of diagnostic specificity and sensitivity for the identification of patients with CD, especially in those with IgA deficiency, as well as in other diseases associated with sensitivity to gluten, monitoring the effect of the gluten-free diet. The combined determination of a panel of autoantibodies related to CD, including the anti-DGP antibodies, improves the diagnose process and follow-up of these patients.